It is well known that many medicines are a mixture of two enantiomers, or mirror-image molecules. Two enantiomers occur when a molecule has a single chiral centre and the two mirror images, called S or L (left handed) and R or D (right handed), are usually found in equal amounts in the parent (racemic) mixture. While for many compounds used in clinical practice the active moiety is found in one of the two enantiomers with the other being seen as an unnecessary and redundant component of the racemic mixture, the difference between enantiomers can mean a difference between therapeutic and adverse effects, as well as in beneficial pharmacological effect and potency.
Ariens EJ ( 1984) Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol26: 663-668.
2.
Boyle J., Trick L., Johnsen S., Roach J. and Rubens R. ( 2008) Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone. Hum Psychopharmacol23: 385-397.
3.
Brunello N., Bettica P., Amato D., Maier G. and Nutt D. ( 2008) Pharmacokinetics of (S)-zopiclone and (S)-desmethylzopiclone following dosing with zopiclone and eszopiclone. Eur Neuropsychopharmacol18: S581.
4.
Brunello N., Cooper J., Bettica P., Maier G. and Nutt D. ( 2009) Differential pharmacological profiles of the GABAA receptor modulators zolpidem, zopiclone, eszopiclone and (S)-desmethylzopiclone. Abstract Presented at the World Psychiatric Association (WPA) International Congress, Florence.
5.
Chen F., Larsen MB, Neubauer HA, Sánchez C., Plenge P. and Wiborg O. ( 2005a) Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem92: 21-28.
6.
Chen F., Larsen MB, Sánchez C. and Wiborg O. ( 2005b) The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol15: 193-198.
7.
Cipriani A., Furukawa TA, Salanti G., et al. (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet373: 746-758.
8.
El-Mansari M., Sánchez C., Chouvet G., Renaud B. and Haddjeri N. ( 2005) Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology2005; 30: 1269-1277.
9.
El-Mansari ME, Wiborg O., Mnie-Filali O., Benturquia N., Sánchez C. and Haddjeri N. ( 2007) Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies. Int J Neuropsychopharmacol10: 31-40.
10.
Fernandez C., Maradeix V., Gimenez F., Thuillier A. and Farinotti R. ( 1993) Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos21: 1125-1128.
11.
Fish EW, Faccidomo S., Gupta S. and Miczek KA ( 2004) Anxiolyticlike effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups. J Pharmacol Exp Ther308: 474-480.
12.
Grundemar L., Wohlfart B., Lagerstedt C., Bengtsson F. and Eklundh G. ( 1997) Symptoms and signs of severe citalopram overdose. Lancet349: 1602.
13.
Hayes BD, Klein-Schwartz W., Clark RF, Muller AA and Miloradovich JE ( 2008) Comparison of toxicity of overdoses with citalopram and escitalopram. Clin Toxicol46: 629.
14.
Ho R., Norman RF, van Veen MM and Anderson IB ( 2004) A 3-year review of citalopram and escitalopram ingestions . J Toxicol Clin Toxicol42: 746.
15.
Isbister GK, Bowe SJ, Dawson A., et al. (2004) Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol42: 277-285.
16.
Kasper S., Sacher J., Klein N., et al. (2009) Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram . Int Clin Psychopharmacol24: 119-125.
17.
Kelly CA, Dhaun N., Laing WJ, et al. (2004) Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol42: 67-71.
18.
Klein N., Sacher J., Geiss-Granadia T., et al. (2007) Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. Psychopharmacology (Berl)191: 333-339.
19.
Krystal AD, Walsh JK, Laska E., et al. (2003) Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep26: 793-799.
20.
Lundberg J., Christophersen JS, Petersen KB, Loft H., Halldin C. and Farde L. ( 2007) PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int J Neuropsychopharmacol10: 777-785.
21.
McMahon LR, Jerussi TP and France CP ( 2003) Stereoselective discriminative stimulus effects of zopiclone in rhesus monkeys. Psychopharmacology (Berl)165: 222-228.
22.
Mnie-Filali O., Faure C., Mansari ME, et al. (2007) R-citalopram prevents the neuronal adaptive changes induced by escitalopram. Neuroreport18: 1553-1556.
23.
Montgomery SA, Loft H., Sánchez C., Reines EH and Papp M. ( 2001) Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol88: 282-286.
24.
Moore N., Verdoux H. and Fantino B. ( 2005) Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol20: 131-137.
25.
Mørk A., Kreilgaard M. and Sánchez C. ( 2003) The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats . Neuropharmacology45: 167-173.
26.
Nutt DJ, Besson M., Wilson SJ, Dawson GR and Lingford-Hughes AR ( 2007) Blockade of alcohol’s amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology53: 810-820.
27.
Nutt DJ and Stahl SM(2010) Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol24: 1-12.
28.
Owens MJ, Knight DL and Nemeroff CB ( 2001) Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry50: 345-350.
29.
Petroski RE, Pomeroy JE, Das R., et al. (2006) Indiplon is a high-affinity positive allosteric modulator with selectivity for α1 subunit-containing receptors. JPET317: 369-377.
30.
Personne M., Persson H. and Sjoberg G. ( 1997) Citalopram toxicity. Lancet350: 518-519.
31.
Plenge P., Gether U. and Rasmussen SG ( 2007) Allosteric effects of R- and S-citalopram on the human 5-HT transporter: evidence for distinct high- and low-affinity binding sites . Eur J Pharmacol567: 1-9.
32.
Roth T., Walsh JK, Krystal A., Wessel T. and Roehrs TA ( 2005) An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med6: 487-495.
33.
Sánchez C. ( 2006) The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol99: 91-95.
34.
Sánchez C., Bøgesø KP, Ebert B., Reines EH and Braestrup C. ( 2004) Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl)174: 163-176.
35.
Sánchez C., Gruca P., Bien E. and Papp M. ( 2003a) R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol Biochem Behav75: 903-907.
36.
Sánchez C., Gruca P. and Papp M. ( 2003b) R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol14: 465-470.
37.
Sánchez C. and Kreilgaard M. ( 2004) R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav77: 391-398.
38.
Sanna E., Busonero F., Talani G., et al. (2002) Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes. Eur J Pharmacol451: 103-110.
39.
Stórustovu S., Sánchez C., Pörzgen P., et al. (2004) R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter . J Pharmacol142: 172-180.
40.
Tan KR, Brown M., Labouebel GM, et al. (2010) Neural bases for addictive properties of benzodiazepines . Nature463: 769-773.
41.
Teo SK, Colburn WA, Tracewell WG, et al. (2004) Clinical pharmacokinetics of thalidomide . Clin Pharmacokinet43: 311-327.
42.
Wu EQ, Ben-Hamadi R., Yu AP, Tang J., Haim Erder M. and Bose A. ( 2010) Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. J Med Econ, 13: 314-323.
43.
Yilmaz Z., Ceschi A., Rauber-Lüthy C., et al. (2010) Escitalopram causes fewer seizures in human overdose than citalopram. Clin Toxicol (Phila)48: 207-210.
44.
Zammit GK, McNabb LJ, Caron J., Amato DA and Roth T. ( 2004) Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin20: 1979-1991.
45.
Zhong H., Hansen KB, Boyle NJ, et al. (2009) An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett462: 207-212.
